Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Lin, Shih Chang ^a   Liu, Wen Chun ^a   Jan, Jia Tsrong ^b   Wu, Suh Chin ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EPITOPE; GLYCAN; HEMAGGLUTININ; IMMUNOGLOBULIN G; INFLUENZA VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; MUTANT PROTEIN; POLYSACCHARIDE; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; AVIAN INFLUENZA; AVIAN INFLUENZA VIRUS; BINDING SITE; CLADISTICS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMAGGLUTINATION; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PROTEIN BINDING; RECEPTOR BINDING; ADENOVIRIDAE; ANIMAL; BAGG ALBINO MOUSE; CHEMICAL STRUCTURE; CROSS PROTECTION; GENE VECTOR; HEMAGGLUTINATION INHIBITION TEST; IC50; IMMUNIZATION; IMMUNOLOGY; INFLUENZA A VIRUS (H5N1); METABOLISM; ORTHOMYXOVIRUS INFECTION; SPECIES DIFFERENCE; VIROLOGY;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CROSS PROTECTION; FEMALE; GENETIC VECTORS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININS; IMMUNIZATION; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INHIBITORY CONCENTRATION 50; MICE, INBRED BALB C; MODELS, MOLECULAR; MUTANT PROTEINS; ORTHOMYXOVIRIDAE INFECTIONS; POLYSACCHARIDES; RECOMBINANT PROTEINS; SPECIES SPECIFICITY;

EID: 84899892665     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092822     Document Type: Article

References (48)

1. World Health Organization. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. Available at: http://www.who.int/ influenza/human-animal-interface/H5N1-cumulative-table-archives/en/. Accessed Jan 2014.
2. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E et al. (2012) Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336: 1534-1541.
3. Imai M, Watanabe T, Hatta M, Das SC, Ozawa M et al. (2012) Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486: 420-428.
4. Zhang Y, Zhang Q, Kong H, Jiang Y, Gao Y et al. (2013) H5N1 Hybrid Viruses Bearing 2009/H1N1 Virus Genes Transmit in Guinea Pigs by Respiratory Droplet. Science 340(6139): 1459-63.
5. Gao R, Cao B, Hu Y, Feng Z, Wang D et al. (2013) Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus. N Engl J Med 368(20): 1888-97.
6. Uyeki TM, Cox NJ (2013) Global Concerns Regarding Novel Influenza A (H7N9) Virus Infections. N Engl J Med 368(20): 1862-4.
7. WHO/OIE/FAO H5N1 Evolution Working Group (2012) Continued evolution of highly pathogenic avian influenza A (H5N1): updated nomenclature. Influenza Other Respir Viruses 6(1): 1-5.
8. Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B et al. (2011) Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 203: 1729-1738.
9. Beran J, Abdel-Messih IA, Raupachova J, Hobzova L, Fragapane E (2010). A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. Clin Ther 32: 2186-2197.
10. Cox RJ, Pedersen G, Madhun AS, Svindland S, Saevik M et al. (2011) Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial. Vaccine 29: 8049-8059.
11. Forrest HL, Khalenkov AM, Govorkova EA, Kim JK, Del Giudice G et al. (2009) Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets. Vaccine 27: 4187-4195.
12. Yang P, Duan Y, Zhang P, Li Z, Wang C et al. (2012) Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination. PLoS One 7: e30252.
13. Ducatez MF, Bahl J, Griffin Y, Stigger-Rosser E, Franks J et al. (2011) Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development. Proc Natl Acad Sci U S A 108: 349-354.
14. Chen MW, Cheng TJ, Huang Y, Jan JT, Ma SH et al. (2008) A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci U S A 105: 13538-13543.
15. Chen MW, Liao HY, Huang Y, Jan JT, Huang CC et al. (2011) Broadly neutralizing DNA vaccine with specific mutation alters the antigenicity and sugar-binding activities of influenza hemagglutinin. Proc Natl Acad Sci U S A 108: 3510-3515.
16. Rao S, Kong WP, Wei CJ, Yang ZY, Nason M et al. (2008) Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. PLoS One 3: e2432.
17. Wang S, Hackett A, Jia N, Zhang C, Zhang L et al. (2011) Polyvalent DNA vaccines expressing HA antigens of H5N1 influenza viruses with an optimized leader sequence elicit cross-protective antibody responses. PLoS One 6: e28757.
18. Zhou F, Wang G, Buchy P, Cai Z, Chen H et al. (2012) A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses. J Virol 86: 6970-6978.
19. Lin SC, Lin YF, Chong P, Wu SC (2012) Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles. PLoS One 7: e39075.
20. Lin SC, Huang MH, Tsou PC, Huang LM, Chong P et al. (2011) Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines. PLoS One 6: e20052.
21. Huang MH, Lin SC, Hsiao CH, Chao HJ, Yang HR et al. (2010) Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS One 5: e12279.
22. Laursen NS, Wilson IA (2013) Broadly neutralizing antibodies against influenza viruses. Antiviral Res 98: 476-483.
23. Kanekiyo M, Wei CJ, Yassine HM, McTamney PM, Boyington JC et al. (2013) Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature. 499(7456): 102-6.
24. Yang ZY, Wei CJ, Kong WP, Wu L, Xu L et al. (2007) Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. Science 317: 825-828. (Pubitemid 47257924)
25. Okuno Y, Isegawa Y, Sasao F, Ueda S (1993) A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 67: 2552-2558. (Pubitemid 23118850)
26. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB et al. (2010) Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329: 1060-1064.
27. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P et al. (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3: e3942.
28. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A et al. (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333: 850-856.
29. Das SR, Hensley SE, David A, Schmidt L, Gibbs JS et al. (2011) Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategy. Proc Natl Acad Sci U S A 108: E1417-1422.
30. Stansell E, Desrosiers RC (2010) Functional contributions of carbohydrate on AIDS virus glycoprotein. Yale J Biol Med 83: 201-208.
31. Lin SC, Liu WC, Lin YF, Huang YH, Liu JH et al. (2013) Heterologous prime-boost immunization regimens using adenovirus vector and virus-like particles induce broadly neutralizing antibodies against H5N1 avian influenza viruses. Biotechnol J. 8: 1315-1322.
32. Kaverin NV, Rudneva IA, Ilyushina NA, Varich NL, Lipatov AS et al. (2002) Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J Gen Virol 83: 2497-2505.
33. Medina RA, Stertz S, Manicassamy B, Zimmermann P, Sun X et al. (2013) Glycosylations in the Globular Head of the Hemagglutinin Protein Modulate the Virulence and Antigenic Properties of the H1N1 Influenza Viruses. Sci Transl Med 5(187): 187ra170.
34. Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G et al. (2012) Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489: 526-532.
35. Lee PS, Yoshida R, Ekiert DC, Sakai N, Suzuki Y et al. (2012) Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc Natl Acad Sci U S A 109: 17040-17045.
36. Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D et al. (2009) Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog. 5: e1000350.
37. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF et al. (2011) A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol 85: 10905-10908.
38. Tsibane T, Ekiert DC, Krause JC, Martinez O, Crowe JE Jr et al. (2012) Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. PLoS Pathog 8: e1003067.
39. Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J et al. (2011) Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A 108: 14216-14221.
40. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R et al. (2012) Highly conserved protective epitopes on influenza B viruses. Science 337: 1343-1348.
41. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
42. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M et al. (2011) A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333: 843-850.
43. Sui J, Hwang WC, Perez S, Wei G, Aird D et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struc Mol Biol 16: 265-273.
44. Bommakanti G, Citron MP, Hepler RW, Callahan C, Heidecker GJ et al. (2010) Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci U S A 107: 13701-13706.
45. Bommakanti G, Lu X, Citron MP, Najar TA, Heidecker GJ, ter Meulen J et al. (2012) Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J Virol 86: 13434-13444.
46. Schneemann A, Speir JA, Tan GS, Khayat R, Ekiert DC et al. (2012) A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. J Virol 86: 11686-11697.
47. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q et al. (2010) Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1(1): pii: e00018-10.
48. Wei CJ, Yassine HM, McTamney PM, Gall JG, Whittle JR et al. (2012) Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. Sci Transl Med 4(147): 147ra114.